Pfizer ($PFE) is cutting more than 500 jobs in Germany, amounting to one in 8 of the company's workforce there, Handelsblatt is reporting. And in a story that's familiar after several years of sales layoffs, drug reps will bear the brunt of the cuts, although administrative functions will be hit, too.
The job cuts are part of Pfizer's previously announced global restructuring, which is intended to claim more than 20,000 jobs and save billions annually. Some of the cuts came from the integration of Wyeth, which Pfizer bought in 2009; some have been aimed at reducing R&D spending.
And some have stemmed from a shift toward smaller sales forces supporting more specialized drugs--and a shift away from the huge armies of reps that once promoted mass-market blockbusters, such as the best-selling Lipitor, which faces generic competition in November. Most of the German cuts will come in Pfizer's primary-care operations, Handelsblatt states.
But Germans are wondering whether the cuts in were inspired--at least in part--by the government's new austerity plans for drug spending (something Pfizer is hinting at). Pfizer's pain drug Lyrica is expected to face a price cap, for instance, and new drugs will have to prove themselves better than existing treatments during their first year on the market or face government-imposed prices. As a Pfizer spokesman said (as quoted by The Local), "The healthcare policy environment has clearly clouded the expectations for future business."
- see the story in The Local